Opioid Approvals: Congress Wants US FDA Guidance On Abuse Potential

Instead of creating new mandate, legislation tells FDA to outline how risk-benefit decisions could be influenced by a product's abuse potential under existing approval authority; final opioids package expected to reach the White House soon.